Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Dr Reddys Laboratories: Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one may buy Dr Reddys Laboratories as the stock may test new lifetime highs.

    • Prefer pharma, IT services space: Bhuvnesh Singh

      Bhuvnesh Singh, MD & Head of India Research at Barclays prefer pharma and IT services space.

    • Positive on pharma; Sun Pharma, Dr Reddy's, Lupin: Patnaik

      Tirthankar Patnaik, EVP - Institutional Sales at Religare Capital Markets is positive on pharma space.

    • Buy Lupin, Cipla, Dr Reddys Lab: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com advises buying Lupin, Divis Laboratories, Sun Pharmaceutical Industries, Cipla and Dr Reddys Laboratories.

    • Super Six buy/sell calls for January 10

      Vikrant Jadeja of Vibrant Trades suggests buying Jindal Steel & Power with a target of Rs 283 and selling DLF with a target of Rs 150.

    • Buy Dr Reddys Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddys Laboratories as the stock may head higher.

    • Buy Dr Reddys Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddys Laboratories.

    • Buy Dr Reddys Laboratories: Amit Gupta

      Amit Gupta, head-derivatives at ICICI Direct is of the view that one may buy Dr Reddys Laboratories at around Rs 2460-2470 as the stock may go beyond Rs 2600.

    • Prefer HCL Tech, TCS, Tata Steel, UPL, Dabur: Joshi

      Mayuresh Joshi of Angel Broking prefers HCL Technologies and Tata Consultancy Services (TCS) from the IT pack where the earnings growth both in dollar and rupee terms will be exceptional for these companies going forward.

    • Hold Dr Reddy's Labs, Cipla: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may carry positions on the long side in pharma stocks including Cipla and Dr Reddys Laboratories.

    • Dr Reddy's Labs may head higher: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that Dr Reddys Laboratories may touch new life-time highs.

    • Bullish on Lupin, Aurobindo; cautious on Ranbaxy: Religare

      Arvind Bothra, vice president of institutional research at Religare Capital Markets is cautious on Ranbaxy because the earnings visibility is very low and believes that the expectations of a turnaround in the US business etc are seemingly priced-in the stock.

    • Lupin, Sun Pharma, Dr Reddy's top picks: Arvind Bothra

      Arvind Bothra, vice president of institutional research at Religare Capital Markets says Lupin, Sun Pharmaceutical Industries and Dr Reddy's are top picks in the pharma space.

    • Pick Cipla, Dr Reddys Labs: Sriram Rathi

      Sriram Rathi, pharma analyst at Anand Rathi is of the view that one may pick Cipla and Dr Reddys Laboratories from largecap pharma space.

    • Hold Glenmark, Cipla; prefer HCL Tech, KPIT: Deven Choksey

      According to Deven Choksey, MD of KR Choksey Shares and Securities, one can prefer HCL Technologies and KPIT Technologies within the IT space and Glenmark Pharma and Cipla from pharma space.

    • Prefer Sun Pharma, Dr Reddy's Lab, Lupin: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one may prefer Sun Pharmaceutical Industries, Dr Reddys Laboratories and Lupin from largecap pharma space.

    • Pick Dr Reddys Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may pick Dr Reddys Laboratories and Lupin.

    • Super Six stocks that could do well today

      Hemen Kapadia of KR Choksey Securities suggests buying Asian Paints with a target of Rs 505 and Dr Reddys Laboratories with a target of Rs 2493.

    • Prefer Dr Reddy's Labs, Aurobindo Pharma: Ajay Bodke

      Ajay Bodke, Head - Investment Strategy & Advisory at Prabhudas Lilladher advises to prefer Dr Reddys Laboratories, Glenmark Pharma and Aurobindo Pharma from the pharma space.

    • Prefer IT, pharma stocks: Dipan Mehta

      Dipan Mehta, Member of BSE & NSE is of the view that one may prefer IT and pharma stocks.

    • Pharma looks attractive; prefer IT on dips: Raamdeo Agrawal

      According to Raamdeo Agrawal, Joint MD at Motilal Oswal Fin Svcs, pharma sector remains a very desirable portfolio candidate.

    • Prefer IT, pharma stocks: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher is of the view that one may prefer pharma and IT stocks.

    • Go long in JSW Steel, Dr Reddy's Labs: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Broker recommends going long in JSW Steel at current levels as the stock may test Rs 960-970.

    • Accumulate Infosys, Tech Mahindra: Nischal Maheshwari

      Nischal Maheshwari of Edelweiss Financial Services is of the view that one may accumulate Infosys, Tech Mahindra and Persistent Systems from the IT space.

    • Buy Sun Pharma, Cipla: Gopi Suvanam

      According to Gopi Suvanam, Founder of InvestWorks, one may buy Cipla and Sun Pharmaceutical Industries in the pharma space.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347